Johnson & Johnson news

   Watch this stock
Showing stories 1 - 10 of about 70   

Articles published

JNJ 124.89 -0.14 (-0.11%)
price chart
Johnson & Johnson Prostate Cancer Drug Impresses
A new study shows that Johnson & Johnson's prostate cancer pill Zytiga dramatically slows the progression of the disease in men who are not yet sick enough to start chemotherapy.
Johnson & Johnson Latest Company To Break Away From ALEC
Johnson & Johnson is the latest company to break away from the American Legislative Exchange Council (ALEC). On June 12, Johnson & Johnson announced it would stop funding the group that has pushed states to pass voter ID and stand-your-ground ...
Johnson & Johnson Should Split Up Says Goldman
By Peter Loftus. Johnson & Johnson should split into three companies, which could value health-care conglomerate at $76 a share, up more than 20% from current price of $62, Goldman Sachs says.
Johnson & Johnson Announces Completion of Synthes Acquisition
NEW BRUNSWICK, N.J., June 14, 2012 /PRNewswire-FirstCall/ -- Johnson & Johnson (NYSE: JNJ) today announced the completion of the acquisition of Synthes, Inc. for a total purchase price of $19.7 billion in cash and stock.
Johnson & Johnson's $19.7B Synthes Deal: A Surprise Earnings Boost  Forbes
Johnson & Johnson completes $20B takeover of Synthes  Bizjournals.com
Cramer: Johnson & Johnson Could Unlock Value by Splitting Up
Take Johnson & Johnson, for example. The New Brunswick, N.J.-based company makes everything from Band-Aids and Tylenol to knee implants and prescription drugs, all of which are fairly resistant to a global slowdown, Cramer said.
BREAKING: Johnson & Johnson Drops ALEC
Johnson and Johnson has been facing mounting pressure following a push from Color of Change and other progressive groups to leave the conservative agenda-setting group.
Johnson & Johnson Receives US Regulatory Clearance for Synthes Acquisition ...
NEW BRUNSWICK, N.J., June 12, 2012 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced that it has received U.S.
Class Action Launched Concerning Johnson & Johnson Discontinuance of Several ...
These Johnson & Johnson Mesh products were marketed to correct Stress Urinary Incontinence and Pelvic Organ Prolapse. Health Canada first licensed the products for sale and use in Canada on August 19, 1998.
Johnson & Johnson to stop selling surgical mesh  Fox News
J&J Tells Judge It Will Stop Sales of Vaginal Implants  Bloomberg
Johnson & Johnson diabetes drug tops older therapies in studies
An experimental treatment for type 2 diabetes developed by Johnson & Johnson demonstrated greater reduction in blood sugar than Merck & Co's Januvia and an older common treatment, glimepiride, according to data from a pair of late stage clinical trials.
Johnson & Johnson's Favorable Ratings: Does The Market Prefer Trademarks Or ...
Analysts are starting to like Johnson & Johnson again. (Disclaimer: I have now exhausted my knowledge of markets.) What drives the value of companies these days, brand power (trademarks) or brain power (patents)?